AU2016369520B2 - Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine - Google Patents

Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine Download PDF

Info

Publication number
AU2016369520B2
AU2016369520B2 AU2016369520A AU2016369520A AU2016369520B2 AU 2016369520 B2 AU2016369520 B2 AU 2016369520B2 AU 2016369520 A AU2016369520 A AU 2016369520A AU 2016369520 A AU2016369520 A AU 2016369520A AU 2016369520 B2 AU2016369520 B2 AU 2016369520B2
Authority
AU
Australia
Prior art keywords
compound
slurry
mixture
hours
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016369520A
Other languages
English (en)
Other versions
AU2016369520A1 (en
Inventor
Craig Bates
Jianmin Mao
David P. Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of AU2016369520A1 publication Critical patent/AU2016369520A1/en
Application granted granted Critical
Publication of AU2016369520B2 publication Critical patent/AU2016369520B2/en
Priority to AU2021202610A priority Critical patent/AU2021202610B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2016369520A 2015-12-17 2016-12-16 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine Ceased AU2016369520B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021202610A AU2021202610B2 (en) 2015-12-17 2021-04-28 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268758P 2015-12-17 2015-12-17
US62/268,758 2015-12-17
PCT/US2016/067161 WO2017106639A1 (en) 2015-12-17 2016-12-16 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202610A Division AU2021202610B2 (en) 2015-12-17 2021-04-28 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Publications (2)

Publication Number Publication Date
AU2016369520A1 AU2016369520A1 (en) 2018-06-07
AU2016369520B2 true AU2016369520B2 (en) 2021-02-18

Family

ID=59057623

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016369520A Ceased AU2016369520B2 (en) 2015-12-17 2016-12-16 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
AU2021202610A Ceased AU2021202610B2 (en) 2015-12-17 2021-04-28 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021202610A Ceased AU2021202610B2 (en) 2015-12-17 2021-04-28 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Country Status (16)

Country Link
US (4) US9834519B2 (enExample)
EP (2) EP4015508A1 (enExample)
JP (2) JP6940504B2 (enExample)
KR (1) KR20180085814A (enExample)
CN (2) CN114874149A (enExample)
AU (2) AU2016369520B2 (enExample)
BR (1) BR112018012325A2 (enExample)
CA (1) CA3006077A1 (enExample)
EA (1) EA201891431A1 (enExample)
HK (1) HK1255014A1 (enExample)
IL (1) IL259557A (enExample)
MX (2) MX385672B (enExample)
NZ (1) NZ742785A (enExample)
SG (1) SG11201804601TA (enExample)
TW (1) TWI748972B (enExample)
WO (1) WO2017106639A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036295B1 (ru) 2015-12-17 2020-10-22 Аркьюл, Инк. Твердые формы замещенных 5,6-дигидро-6-фенилбензо[f]изохинолин-2-аминовых соединений
CA3006077A1 (en) * 2015-12-17 2017-06-22 Arqule, Inc. Methods for preparing polymorphs of substituted 5,6-dihydrobenzo[h]quinazolin-2-amine
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
US10878412B2 (en) * 2019-05-13 2020-12-29 Truist Bank In-line verification of transactions
WO2022053708A1 (en) 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
US6133257A (en) * 1997-06-20 2000-10-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
WO2010078421A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN101115749B (zh) * 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法
CN101622252B (zh) 2006-12-29 2015-04-22 里格尔制药公司 用作axl抑制剂的取代三唑
GB2449293A (en) * 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
US8815854B2 (en) * 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
JP2017516463A (ja) * 2014-03-31 2017-06-22 デバイオファーム インターナショナル エスエイ Ｆｇｆｒ融合体
EA036295B1 (ru) 2015-12-17 2020-10-22 Аркьюл, Инк. Твердые формы замещенных 5,6-дигидро-6-фенилбензо[f]изохинолин-2-аминовых соединений
CA3006077A1 (en) * 2015-12-17 2017-06-22 Arqule, Inc. Methods for preparing polymorphs of substituted 5,6-dihydrobenzo[h]quinazolin-2-amine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
US6133257A (en) * 1997-06-20 2000-10-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
WO2010078421A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds

Also Published As

Publication number Publication date
US10093632B2 (en) 2018-10-09
AU2016369520A1 (en) 2018-06-07
US11279679B2 (en) 2022-03-22
AU2021202610B2 (en) 2022-06-02
CN108602779A (zh) 2018-09-28
US20180065937A1 (en) 2018-03-08
CN114874149A (zh) 2022-08-09
MX385672B (es) 2025-03-18
US9834519B2 (en) 2017-12-05
US10766868B2 (en) 2020-09-08
JP2018537495A (ja) 2018-12-20
TWI748972B (zh) 2021-12-11
MX2018007415A (es) 2018-11-09
US20190241527A1 (en) 2019-08-08
BR112018012325A2 (pt) 2018-12-04
EP4015508A1 (en) 2022-06-22
NZ742785A (en) 2023-06-30
IL259557A (en) 2018-07-31
SG11201804601TA (en) 2018-07-30
US20170174637A1 (en) 2017-06-22
EP3390368A4 (en) 2019-07-03
US20200102276A1 (en) 2020-04-02
KR20180085814A (ko) 2018-07-27
TW201733992A (zh) 2017-10-01
HK1255014A1 (zh) 2019-08-02
AU2021202610A1 (en) 2021-05-27
EA201891431A1 (ru) 2018-11-30
JP6940504B2 (ja) 2021-09-29
WO2017106639A1 (en) 2017-06-22
MX2020012771A (es) 2022-10-04
EP3390368A1 (en) 2018-10-24
JP2021191782A (ja) 2021-12-16
CA3006077A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
AU2021202610B2 (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
US11912667B2 (en) Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
AU2022201947B2 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
US20250099493A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
HK40079039A (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
KR20230118883A (ko) Enpp1 억제제로서의 이미다졸 화합물
JP2011515493A (ja) 抗原受容体により誘導されるＮＦ−κＢの活性化の阻害剤
EA042753B1 (ru) Способы получения полиморфа дигидрохлорида замещенного 5,6-дигидро-6-фенилбензо[f]изохинолин-2-амина

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)